HAIM
BMY.RT

Hunter Associates Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Hunter Associates Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,807
Closed -$21K – 211
2020
Q4 		$21K Sell
29,807
-102
-0.3% -$217 0.01% 198
2020
Q3 		$67K Hold
29,909
– – 0.02% 180
2020
Q2 		$107K Buy
29,909
+286
+1% +$1.03K 0.03% 172
2020
Q1 		$113K Hold
29,623
– – 0.04% 143
2019
Q4 		$89K Buy
+29,623
New +$77K 0.03% 169

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Hunter Associates Investment Management's BMY.RT Position: Q1 2021 in Review

Hunter Associates Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 29,807 shares — an estimated $21K sold.

Hunter Associates Investment Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $113K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Hunter Associates Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Hunter Associates Investment Management sold 29,807 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $21K.
  • Hunter Associates Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Hunter Associates Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $113K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Hunter Associates Investment Management's 13F filing for Q1 2021, filed 10 May 2021.